Clinical Trials Directory

Trials / Completed

CompletedNCT05161247

Reproductive Outcome After Sperm Selection for Intracytoplasmic Sperm Injection (ICSI) Using Zona Pellucida Proteins

Assessment of the IVF Outcome Parameters After Sperm Selection by Adhesion to Zona Pellucida Proteins

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
368 (actual)
Sponsor
Nadezhda Women's Health Hospital · Academic / Other
Sex
All
Age
20 Years – 50 Years
Healthy volunteers
Not accepted

Summary

The aim of this study is to analyze the effect of a sperm selection method by adhesion to partners' zona pellucida proteins on the assisted reproduction treatment (ART) outcome parameters.

Detailed description

The success rate after treatment by in-vitro fertilisation (IVF) depends on the sperm selection process. Classical sperm selection techniques are based on the spermatozoa morphology and motility, therefore are not able to measure the sperm ability to recognise the oocyte. Furthermore it is known that semen samples showing higher adherence rate to zona pellucida have higher fertilisation potential than spermatozoa that fail to bind to zona proteins. There have been numerous reports on applying partner' native zona pellucida in sperm selection prior ICSI. However, these studies imply the whole native zona pellucida, while this study will focus on the application of acid-solubilized zonae pellucidae. Here in this study, the aim is to assess the fertilisation rate, the number and quality of the formed embryos, implantation and ongoing pregnancy success after sperm selection for ICSI by their ability to adhere to immobilized zona pellucida proteins.

Conditions

Interventions

TypeNameDescription
OTHERZona pellucida sperm selectionSperm selection for ICSI based on the spermatozoa ability to adhere to immobilized zona pellucida proteins.
OTHERConventional sperm selectionSperm selection for ICSI based on the sperm morphology.
OTHERIntracytoplasmic Sperm Injection (ICSI)Normal ICSI procedure.

Timeline

Start date
2021-12-03
Primary completion
2024-03-03
Completion
2024-07-05
First posted
2021-12-17
Last updated
2025-05-21

Locations

1 site across 1 country: Bulgaria

Source: ClinicalTrials.gov record NCT05161247. Inclusion in this directory is not an endorsement.